Type I Interferon (IFN-1) Talks and Poster Sessions
Blue highlighting denotes pharma trial
Sunday, November 12, 2023
- 9:00 AM – 11:00 AM PT
-
0069: Efficacy of Cenerimod in Patients with High IFN-1 Gene Expression Signature and High Anti-dsDNA Antibody Levels: Post Hoc Analysis from a Phase II Trial
Location: Poster Hall
Abstract Poster Presenter: Anka Askanase, MD, MPH. – Columbia University Medical Center
-
- 9:00 AM – 11:00 AM PT
-
0055: Elevated LINE-1 Expression in SLE Keratinocytes Leads to LINE-1 Reverse Transcriptase-dependent Type I Interferon Responses
Location: Poster Hall
Abstract Poster Presenter: Wenyan Miao, PhD – Rome Therapeutics
-
- 9:00 AM – 11:00 AM PT
-
0072: Circulating T-cell Immunosenescence Is High in Patients with Immune-Mediated Inflammatory Diseases (IMIDs) and Is Associated with Interferons
Location: Poster Hall
Abstract Poster Presenter: Samuel Bitoun, MD, PhD – CHU Bicêtre APHP
-
- 9:00 AM – 11:00 AM PT
-
0205: Changes in Serum Rheumatoid Factor Following Eradication of Hepatitis C Virus Infection with Interferon or Direct Antiviral Therapy
Location: Poster Hall
Abstract Poster Presenter: Jamie Chieh Lo, -None- – School of Medicine, I-Shou University
-
- 9:00 AM – 11:00 AM PT
-
0548: Clinical and Interferon Biomarkers to Exclude Imminent Autoimmune Disease in ANA Positive Individuals
Location: Poster Hall
Abstract Poster Presenter: Md Yuzaiful Md Yusof, PhD, MBChB, MRCP (he/him/his) – University of Leeds
-
- 12:15 PM - 1:30 PM PT
-
203: SAPHNELO® (anifrolumab-fnia): A First-in-class IFN-1 Signaling Inhibitor, Now with 4-Year Data from a Long-term Safety and Tolerability Study
Location: Theater A
Industry Presenter: Maureen McMahon, MD, MS – UCLA David Geffen School of Medicine
-
- 2:15 PM - 2:25 PM PT
-
0728: Systemic Lupus Erythematosus B Lymphocyte Responsiveness to Type I and Type III Interferon Is Determined by Donor IFN Status and B Cell Phenotype
Location: Room 30D-E
Presenting Author: Jennifer Barnas, MD, PhD, BS – University of Rochester
-
- 2:00 PM - 2:10 PM PT
-
0733: Global Identification of Lupus Genetic Risk Variants Facilitating the Type I Interferon Pathway Through CRISPR-based Genomic Screening
Location: Room 32A-B
Presenting Author: Nan Shen, MD, PhD – Shanghai Jiang Tong University School of Medicine
-
- 3:15 PM - 3:25 PM PT
-
0762: Liver Disease Is a Common Feature of HA20 That Causes Significant Morbidity Associated with Interferon Induction
Location: Room 5A-B
Presenting Author: Magdalena Harasimowicz, MD – University of Pittsburgh Medical Center (UPMC)
-
- 2:15 PM - 2:25 PM PT
-
0788: Whole Exome Sequencing and Evolutionary Action Missense Mutation Analysis Identifies MICB as a New SSc Susceptibility Locus and the Interferon Pathway as Contributors to SSc Pathogenesis
Location: Room 6F/6C
Presenting Author: Shamika Ketkar, Ph.D. (she/her/hers) – Baylor College of Medicine
-
- 3:15 PM - 3:25 PM PT
-
0792: Single Cell RNA-seq of Myeloid Cells from Systemic Sclerosis Patients Identifies Circulating Monocyte Population with Interferon Signature Associated with Interstitial Lung Disease
Location: Room 6F/6C
Presenting Author: Richard Ainsworth, n/a – Cedars-Sinai Medical Center
-
Monday, November 13, 2023
- 7:30 AM – 8:15 AM PT
- Meet the Panel: The Latest in Lupus Treatment
Location: Room 6A-B
Panelist: Maria Dall'Era, MD (she/her/hers) – UCSF
Panelist: Richard Furie, MD – Northwell Health
Panelist: Marta Mosca, MD, PhD – University of Pisa
- Meet the Panel: The Latest in Lupus Treatment
- 9:00 AM – 11:00 AM PT
- 0891: Selective and Potent Inhibition of Cyclic GMP-AMP Synthase (cGAS) Fully Normalizes Autoinflammation Across Tissues in a Trex1-/- Mouse Model for Type I Interferonopathies
Location: Poster Hall
Abstract Poster Presenter: Zuzana Licenikova Horejsi, PhD – Institute of Organic Chemistry and Biochemistry of the CAS
- 0891: Selective and Potent Inhibition of Cyclic GMP-AMP Synthase (cGAS) Fully Normalizes Autoinflammation Across Tissues in a Trex1-/- Mouse Model for Type I Interferonopathies
- 9:00 AM – 11:00 AM PT
- 0893: Involvement of Type I Interferon-responsive Myeloid Cells in Renal Inflammation in a Lupus Mouse Model
Location: Poster Hall
Abstract Poster Presenter: Lindsey Han, -None- – Lerner Research Institute, Cleveland Clinic Foundation
- 0893: Involvement of Type I Interferon-responsive Myeloid Cells in Renal Inflammation in a Lupus Mouse Model
- 9:00 AM – 11:00 AM PT
- 0894: The Cellular and Spatial Type I Interferon Response Following Skin Exposure to Ultraviolet Light
Location: Poster Hall
Abstract Poster Presenter: Jie An, PhD – University of Washington
- 0894: The Cellular and Spatial Type I Interferon Response Following Skin Exposure to Ultraviolet Light
- 9:00 AM – 11:00 AM PT
- 0910: 17β-estradiol and B-cell Intrinsic Type I Interferon Amplify Toll-like Receptor 7 Signaling Loop in B Cells of Female Lupus Prone BXD2 Mice
Location: Poster Hall
Abstract Poster Presenter: Kathryn Sullivan, BS – University of Alabama-Birmingham
- 0910: 17β-estradiol and B-cell Intrinsic Type I Interferon Amplify Toll-like Receptor 7 Signaling Loop in B Cells of Female Lupus Prone BXD2 Mice
- 9:00 AM – 11:00 AM PT
- 0919: Investigating the Role of Interferon in Promoting Flares of SLE at a Single Cell Level
Location: Poster Hall
Abstract Poster Presenter: Zoha Faheem, BSc (she/her/hers) – University of Toronto
- 0919: Investigating the Role of Interferon in Promoting Flares of SLE at a Single Cell Level
- 9:00 AM – 11:00 AM PT
- 1176: Brepocitinib Prevents Type-I Interferon Induced Damage in Cultured Myocytes and Endothelial Cells Indicating a Potential Role in the Treatment of Dermatomyositis
Location: Poster Hall
Abstract Poster Presenter: Jiri Vencovsky, MD (he/him/his) – Institute of Rheumatology
- 1176: Brepocitinib Prevents Type-I Interferon Induced Damage in Cultured Myocytes and Endothelial Cells Indicating a Potential Role in the Treatment of Dermatomyositis
- 11:15 AM – 11:25 AM PT
- 1580: CXCL13+ T Cell Differentiation in Systemic Lupus Erythematosus Is Controlled by Opposing Effects of Aryl Hydrocarbon Receptor and Type I Interferon
Location: Exhibit Hall A-B
Plenary Presenter: Calvin Law, PhD (he/him/his) – Northwestern University Feinberg School of Medicine
- 1580: CXCL13+ T Cell Differentiation in Systemic Lupus Erythematosus Is Controlled by Opposing Effects of Aryl Hydrocarbon Receptor and Type I Interferon
- 4:45 PM – 4:55 PM PT
- 1660: Still’s Disease Patients with High Interferon-stimulated Gene Expression Have Enrichment of Rare, de Novo and Recessive Protein Altering Variants in Innate Immune Pathways
Location: Room 7A-B
Presenting Author: Michael Ombrello, MD – National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH)
- 1660: Still’s Disease Patients with High Interferon-stimulated Gene Expression Have Enrichment of Rare, de Novo and Recessive Protein Altering Variants in Innate Immune Pathways
- 4:00 PM – 4:10 PM PT
- 1693: Blood Immunophenotyping Distinguishes Three Subgroups of Lupus Nephritis Patients with Distinct Kidney Infiltrates and Interferon Signatures
Location: Room 6F/6C
Presenting Author: Alice Horisberger, MD – Brigham and Woman's Hospital, Harvard medical school
- 1693: Blood Immunophenotyping Distinguishes Three Subgroups of Lupus Nephritis Patients with Distinct Kidney Infiltrates and Interferon Signatures
- 4:15 PM – 4:25 PM PT
- 1664: Fibroblast Specific Interferon Regulatory Factor 7 (IRF7) Expression Is a Key Link Between Type I Interferon Activation and the Exaggerated Dermal and Pulmonary Fibrosis in Systemic Sclerosis
Location: Room 11A-B
Presenting Author: Minghua Wu, MD, PhD – University of Texas Health Science Center at Houston, McGovern Medical School
- 1664: Fibroblast Specific Interferon Regulatory Factor 7 (IRF7) Expression Is a Key Link Between Type I Interferon Activation and the Exaggerated Dermal and Pulmonary Fibrosis in Systemic Sclerosis
- 4:30 PM – 4:40 PM PT
- 1665: Endothelial Response to Type I Interferon Contributes to Vasculopathy and Fibrosis and Predicts Disease Progression of Systemic Sclerosis
Location: Room 11A-B
Presenting Author: Hanlin Yin, MD – Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital
- 1665: Endothelial Response to Type I Interferon Contributes to Vasculopathy and Fibrosis and Predicts Disease Progression of Systemic Sclerosis
Tuesday, November 14, 2023
- 9:00 AM – 11:00 AM PT
- 1708: In Cis SOCS1 Variants Illustrate the Precise Regulation of Interferon Signaling Needed to Prevent Autoimmunity
Location: Poster Hall
Abstract Poster Presenter: Yan Du, MD, PhD – Harvard medical school
- 1708: In Cis SOCS1 Variants Illustrate the Precise Regulation of Interferon Signaling Needed to Prevent Autoimmunity
- 9:00 AM – 11:00 AM PT
- 1711: CD14+ Monocytes Demonstrate a Unique Transcriptional Signature in Macrophage Activation Syndrome, Highlighting a Role for Interferons and Identifying Putative Hemophagocytes in Circulation
Location: Poster Hall
Abstract Poster Presenter: Susan Canny, MD, PhD – Seattle Children's Hospital/University of Washington
- 1711: CD14+ Monocytes Demonstrate a Unique Transcriptional Signature in Macrophage Activation Syndrome, Highlighting a Role for Interferons and Identifying Putative Hemophagocytes in Circulation
- 9:00 AM – 11:00 AM PT
- 1714: Aberrant Myeloid Populations in the TNF-Transgenic Model of Pulmonary Hypertension Overexpress Interferon Pathways and Are Driven by TNFR1 Signaling
Location: Poster Hall
Abstract Poster Presenter: Gaochan Wang, n/a (he/him/his) – University of Rochester
- 1714: Aberrant Myeloid Populations in the TNF-Transgenic Model of Pulmonary Hypertension Overexpress Interferon Pathways and Are Driven by TNFR1 Signaling
- 9:00 AM – 11:00 AM PT
- 1922: Use of Plasma with High Titer Neutralizing Autoantibodies to Type I Interferons in Patients with Severe Refractory Flare-up of Hidradenitis Suppurativa as Novel Passive Immunotherapy Approach: Trial Protocol
Location: Poster Hall
Abstract Poster Presenter: ERIC TOUSSIROT, MD, PhD (he/him/his) – university hospital of BESANCON
- 1922: Use of Plasma with High Titer Neutralizing Autoantibodies to Type I Interferons in Patients with Severe Refractory Flare-up of Hidradenitis Suppurativa as Novel Passive Immunotherapy Approach: Trial Protocol
- 9:00 AM – 11:00 AM PT
- 2044: Monogenic Interferon Mediated Diseases: Novel Phenotype and Genotype Characteristics from Saudi Population
Location: Poster Hall
Abstract Poster Presenter: Alhanouf Alsaleem, MD, MBBS – KFSH&RC
- 2044: Monogenic Interferon Mediated Diseases: Novel Phenotype and Genotype Characteristics from Saudi Population
- 9:00 AM – 11:00 AM PT
- 2297: Interferon-α as a Biomarker to Predict Flares in Lupus Nephritis
Location: Poster Hall
Abstract Poster Presenter: Laura Whittall Garcia, MD – University Health Network
- 2297: Interferon-α as a Biomarker to Predict Flares in Lupus Nephritis
- 9:00 AM – 11:00 AM PT
- 2333: Dapirolizumab Pegol Impacts Important Immunologic Pathways in SLE: Pharmacodynamic Analysis of B Cell and Type I Interferon Pathways from a Phase 2b Trial
Location: Poster Hall
Abstract Poster Presenter: Christian Stach, MD – UCB Pharma
- 2333: Dapirolizumab Pegol Impacts Important Immunologic Pathways in SLE: Pharmacodynamic Analysis of B Cell and Type I Interferon Pathways from a Phase 2b Trial
- 9:00 AM – 11:00 AM PT
- 2342: Modulation of B Cell and Interferon Pathways by Ianalumab in Patients with Systemic Lupus Erythematosus: Findings from a Phase 2 Clinical Trial
Location: Poster Hall
Abstract Poster Presenter: Isabelle Isnardi, PhD – Novartis Pharma AG
- 2342: Modulation of B Cell and Interferon Pathways by Ianalumab in Patients with Systemic Lupus Erythematosus: Findings from a Phase 2 Clinical Trial
- 2:45 PM – 2:55 PM PT
- 2464: B Cells in Anti-tRNA Synthetase Syndrome Patients Show an Activated, Interferon Responsive Signature
Location: Room 25A-C
Presenting Author: Erin Wilfong, MD, PhD (she/her/hers) – Vanderbilt University Medical Center
- 2464: B Cells in Anti-tRNA Synthetase Syndrome Patients Show an Activated, Interferon Responsive Signature
- 3:00 PM – 3:10 PM PT
- 2477: Anifrolumab Normalizes the Type I Interferon Signature in a Cohort of Patients with Type I Interferonopathies
Location: Room 7A-B
Presenting Author: Sara Alehashemi, MD, MPH – NIH/NIAID/TADS
- 2477: Anifrolumab Normalizes the Type I Interferon Signature in a Cohort of Patients with Type I Interferonopathies
- 3:15 PM – 3:25 PM PT
- 2448: UV Light Exposure Induces a Type I Interferon Dependent Activation and Migration of Inflammatory Dendritic Cells to Local Lymph Nodes
Location: Room 26A-B
Presenting Author: Xizhang Sun, MD, PhD – University of Washington
- 2448: UV Light Exposure Induces a Type I Interferon Dependent Activation and Migration of Inflammatory Dendritic Cells to Local Lymph Nodes
Wednesday, November 15, 2023
- 9:15 AM – 9:25 AM PT
- 2576: Rapid Onset of Response in Adult Dermatomyositis Patients Receiving Anti-interferon β (PF-06823859): Results of a Phase 2, Double-blind, Randomized, Placebo-Controlled Study
Location: Room 23A-C
Presenting Author: Rohit Aggarwal, MD, MS – University of Pittsburgh
- 2576: Rapid Onset of Response in Adult Dermatomyositis Patients Receiving Anti-interferon β (PF-06823859): Results of a Phase 2, Double-blind, Randomized, Placebo-Controlled Study
